Dr. Santin is a skilled gynecologic oncologist and talented clinical scientist who has a strong background in training and mentoring talented young physician-scientists. He has been involved in the training of 15 post-doctoral fellows, including Gynecologic Oncology, Medical Oncology and Surgical Oncology Fellows, the majority of whom have gone on to academic careers in the U.S. and abroad in Gynecologic Oncology and cancer research.
Dr. Santin’s research and clinical accomplishments have been published in high-impact journals in the cancer research field, including the New England Journal of Medicine, Cancer Research, Clinical Cancer Research, and the Journal of Virology, while numerous additional publications have been reported in subspecialty journals. Dr. Santin’s translational research program in ovarian cancer has been funded multiple times by federal agencies including the Department of Defense (DoD), the National Institute of Health (NIH) as well as private National and International Foundations. He is currently funded by NIH to evaluate the potential use of Clostridium Perfringens Enterotoxin (CPE) as a novel therapy against chemotherapy resistant ovarian carcinoma.
His research program spans a range from basic studies in molecular cancer genetics and tumor immunology to translational clinical cancer research testing novel immunotherapeutic strategies and targeted compounds in vivo for the treatment of gynecologic malignancies. Dr. Santin is an active member of the Gynecologic Oncology Group (GOG) and the International Gynecological Cancer Society (IGCS), the two largest organizations of gynecologic oncologists in the world. He is a member of the GOG Developmental Therapeutics Committee, a national Committee that reviews multi-site concepts/protocols to be implemented at nationwide level by the GOG funded by the NIH and he is Chairman for the entire GOG of multiple Phase II clinical studies testing novel biologic agents in patient harboring gynecologic malignancies.
Dr. Santin has initiated and completed multiple investigator’s initiated FDA approved clinical trials in gynecologic patients using novel immunotherapeutic strategies developed and characterized in his own laboratory. Dr. Santin has been awarded multiple patents for the development of new methods for the early diagnosis of ovarian cancer as well as the development of novel immunotherapeutic methods targeting serine proteases highly expressed in ovarian cancer patients.
Dr. Santin also serves as peer reviewer for a number of journals including Lancet, Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research, American Journal of Obstetrics & Gynecology, International Journal of Cancer, British Journal of Cancer, Gynecologic Oncology, International Journal of Radiation Oncology, Obstetrics & Gynecology, Journal of Immunotherapy, International Journal of Gynecological Cancer, Cancer Immunology Immunotherapy, BMC Cancer, Cancer Detection & Prevention, Molecular Cancer Research, Cancer, Cancer Biology & Therapy, Reproductive Sciences.